Table 2.
Descriptives by underreporting status (N = 204).
| Baseline | Follow-Up | |||||
|---|---|---|---|---|---|---|
|
|
||||||
| Underreporters (n=37) |
SR+ (n = 134) |
SR−/PEth− (n=33) |
Underreporters (n=21) |
SR+ (n = 118) |
SR−/PEth− (n=65) |
|
|
|
||||||
| Binary measures, n (%) | ||||||
|
| ||||||
| Low Income | 13 (35.1) | 40 (29.9) | 11 (33.3) | 8 (38.1) | 37 (31.4) | 19 (29.2) |
| AUDIT-C | 5 (13.5) | 47 (35.1) | 5 (15.2) | 1 (4.8) | 33 (28.0) | 3 (4.6) |
| Past-Year Drug Use | 2 (5.4) | 25 (18.7) | 3 (9.1) | 5 (23.8) | 18 (15.3) | 7 (10.8) |
| Past-Month Smoking | 18 (48.7) | 79 (59.0) | 18 (54.6) | 8 (38.1) | 68 (57.6) | 30 (46.2) |
| HCV Antibody Positive | 22 (59.5) | 68 (51.9) | 23 (69.7) | 13 (61.9) | 61 (52.1) | 40 (61.5) |
|
| ||||||
| Self-Reported Quantitative Measures, Mean (SD/interquartile range) | ||||||
|
| ||||||
| Alcohol Outcome Expectancies | 6.1 (3.0/4) | 7.2 (3.1/5) | 6.9 (2.8/6) | 6.5 (3.5/5) | 7.3 (3.4/5) | 7.1 (3.4/6) |
| HIV Symptom Scale Score | 30.7 (8.6/12) | 36.0 (13.3/18) | 40.3 (13.4/16) | 35.3 (14.8/22) | 32.2 (12.8/15) | 32.7 (9.5/13) |
| Overall Health | 2.8 (1.0/1) | 2.9 (0.9/1) | 3.3 (1.0/1) | 3.1 (1.0/1) | 3.0 (0.9/2) | 3.1 (0.9/1) |
| Self-Efficacy | 48.2 (9.2/9) | 46.8 (8.3/12) | 45.0 (7.4/10) | 47.1 (10.0/11) | 46.9 (8.2/12) | 44.5 (10.6/14) |
|
| ||||||
| Biological Quantitative Measures, Medians (interquartile range) | ||||||
|
| ||||||
| Viral Load | 40.0 (98) | 40.0 (25) | 40.0 (130) | 40.0 (50) | 40.0 (37) | 40.0 (42) |
| CD4 Count | 459.0 (258) | 423.0 (256) | 444.0 (296) | 513.0 (368) | 440.5 (319) | 454.0 (268) |
| PEth | 18.0 (11) | 23.5 (38) | – | 14.0 (10) | 17.0 (42) | – |
Note. Underreporters = negative on self-reported alcohol use and positive on PEth; SR+ = positive self-reported alcohol use, PEth positive or negative; SR−/PEth− = negative on both self-reported alcohol use in the past 30 days and PEth. For alcohol outcome expectancies, total n at baseline (follow-up) = 199 (193). For HCV Antibody positive, total n at baseline (follow-up) = 201 (203).